Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 316 participants.

Also called NCT04239950

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 316 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04239950
Other papers using this trial's data
  • Efficacy and safety of highly purified ethyl icosapentate soft capsules (MND-21) for the treatment of severe hypertriglyceridemia: A 12-week, multi-center, placebo-controlled, randomized, double-blind, phase III clinical trial in China Journal of clinical lipidology, 2026-02 DOI, PubMed 41500861

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04239950. Randomized; quadruple masking; primary purpose treatment. Start 2020-05-09 (actual); primary completion 2023-07-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia
Condition
Hypertriglyceridemia
Intervention (Drug)
Placebo
Intervention (Drug)
Ethyl Icosapentate
Lead sponsor
Mochida Pharmaceutical Company, Ltd. (class: industry)
Collaborator
Marubeni Pharmaceuticals (Suzhou) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04239950
Content hash
50030282e3e60ad4c994f5a8721026c2e50a275263f7657081c25d681b9638fc